Summit Therapeutics Inc. Deferred Federal Income Tax Expense (Benefit)
Summit Therapeutics Inc. (SMMT) reported Deferred Federal Income Tax Expense (Benefit) of $0 for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-23.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredFederalIncomeTaxExpenseBenefit · last filed 2026-02-23
- Summit Therapeutics Inc. deferred federal income tax expense (benefit) for fiscal 2025 was $0.00.
- Summit Therapeutics Inc. deferred federal income tax expense (benefit) for fiscal 2024 was $0.00.
- Summit Therapeutics Inc. deferred federal income tax expense (benefit) for fiscal 2023 was $0.00.
- Summit Therapeutics Inc. deferred federal income tax expense (benefit) for fiscal 2022 was $0.00.
| Period end | Deferred Federal Income Tax Expense (Benefit) 11 month | Deferred Federal Income Tax Expense (Benefit) 12 month |
|---|---|---|
| 2025-12-31 | $0.00 10-K · filed 2026-02-23 | |
| 2024-12-31 | $0.00 10-K · filed 2026-02-23 | |
| 2023-12-31 | $0.00 10-K · filed 2025-02-24 | |
| 2022-12-31 | $0.00 10-K · filed 2025-02-24 | |
| 2021-12-31 | $0.00 10-K · filed 2023-03-09 | |
| 2020-12-31 | $0.00 10-K/A · filed 2022-12-21 | |
| 2019-12-31 | -$147.00K 8-K · filed 2020-09-29 | |
| 2019-01-31 | -$935.00K 8-K · filed 2020-09-29 | |
| 2018-01-31 | $0.00 8-K · filed 2020-09-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |